Novel IVD medical device for endometriosis diagnostic.
Test is an in vitro diagnostic real-time reverse transcription-PCR assay intended for quantification of the relative level of expression of the FUT4 mRNA, a marker of endometriosis in relation to the expression of GAPDH reference mRNA. Analysis is performed on RNA isolated from a biopsy taken from a patient's endometrium in the secretory phase of the menstrual cycle, in order to confirm or exclude endometriosis.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Leśna, Warsaw,05-502,poland
- Industry
- Medical Device
- Website
- https://diagendo.com/
- Keywords
- diagnostyka, wyrobymedyczne, medicaldevice, endometrioza, endometriosis, diagnostics, ginekologia, kobieta, zdrowie, gynecology, women, health.
- HQ
- Warsaw
Diagendo Questions
Diagendo's website is https://diagendo.com/
Diagendo's LinkedIn profile is https://pl.linkedin.com/company/diagendo
Diagendo has
2 employees.
View email and phone details for 2
employees at Diagendo.
Diagendo's industry is
Medical Device
Diagendo's categories are Medical Device
Diagendo's founding year is 2022
